Atropine-coma therapy (ACT) represents one of the most drastic and controversial somatic interventions in the mid-twentieth-century psychiatric armamentarium. Emerging during an era characterized by heroic biological experimentation, ACT sought to alleviate intractable psychiatric disorders through the intentional induction of deep anticholinergic delirium and vegetative coma using massive doses of atropine sulfate. While it was heralded by its early proponents as an economical and less technically cumbersome alternative to insulin shock therapy, its severe physiological toxicity, erratic therapeutic efficacy, and high risk profile led to its rapid abandonment following the introduction of modern psychopharmacological agents.
Atropine-Coma Therapy (ACT)
1. Concise Definition
Atropine-coma therapy (ACT) is an obsolete somatic psychiatric treatment developed in the 1950s in which supraphysiological, toxic doses of the belladonna alkaloid atropine sulfate were administered intramuscularly to induce sustained central nervous system depression, pharmacological delirium, and profound coma. The therapeutic protocol was primarily deployed for the management of schizophrenia, severe affective psychoses, and refractory psychoneurotic states, with coma typically interrupted after several hours through the administration of cholinergic agonists such as physostigmine.
As an offshoot of the broader mid-twentieth-century shock-therapy paradigm, ACT operated on the assumption that massive neurochemical disruption and transient suppression of cortical activity could disrupt chronic psychotic ideation and facilitate psychiatric remission. Unlike electroconvulsive therapy or chemical convulsive treatments that induced paroxysmal epileptic seizures, ACT produced an acute anticholinergic toxidrome marked by profound autonomic instability, disorientation, hyperthermia, hypertonia, and comatose unconsciousness.
The clinical trajectory of ACT was extraordinarily brief. Originating in North American psychiatric hospitals in the early 1950s, the procedure was practiced sporadically in institutional settings for approximately two decades before being entirely superseded by the dawn of neuroleptic pharmacotherapy and ethical reforms in biological psychiatry.
2. Etymology & Linguistic Origin
The nomenclature of atropine-coma therapy derives from classical botanical, mythological, and medical roots. The word atropine originates from modern Latin (atropina), coined in the early nineteenth century following the isolation of the tropane alkaloid from the deadly nightshade plant, Atropa belladonna. The genus name Atropa is directly derived from the Ancient Greek mythology of Atropos (Ατροπος, meaning “inexorable,” “inflexible,” or “unturnable”), the oldest of the three Moirai or Fates, whose duty was to cut the thread of human life. This ominous linguistic heritage reflects the potent lethal toxicity inherent to belladonna alkaloids when consumed in uncontrolled quantities.
The term coma originates from the Ancient Greek k&omacron;ma (κῶμα), signifying “deep, lethargic sleep” or “stupor,” which transitioned into medical Latin to define an acute pathological state of profound unconsciousness characterized by an inability to be awakened and a lack of voluntary response to external stimuli. The English suffix therapy traces back through the Latin therapia to the Greek therapeia (θεραπεία), meaning “healing,” “curing,” or “medical attendance,” stemming from the verb therapeuein (“to serve” or “to treat medically”).
The complete compound phrase “atropine-coma therapy”—frequently abbreviated in twentieth-century psychiatric literature as ACT, or occasionally designated as “atropine toxicity therapy” (ATT)—was formally introduced into clinical psychiatric discourse by the American psychiatrist Gordon T. Forrer in 1950. Forrer initially utilized the descriptive phrasing “atropine toxicity in the treatment of mental illness” before the standardized phrase “atropine-coma therapy” gained currency across European and North American institutional literature.
3. Pronunciation & Grammatical Form
The standard phonetic transcription of the term in International Phonetic Alphabet (IPA) notation is:
- Atropine: /ˈætrəpiːn/ or /ˈætrəpɪn/
- Coma: /ˈkoʊmə/
- Therapy: /ˈθɛrəpi/
Grammatically, “atropine-coma therapy” functions as a compound noun phrase in English, where “atropine-coma” serves as an attributive compound modifying the base noun “therapy.” The term is typically treated as an uncountable mass noun when referring to the clinical paradigm (e.g., “the hospital adopted atropine-coma therapy as an experimental measure”), but may be used countably when referring to discrete treatment regimens or sessions (e.g., “the patient received forty consecutive atropine comas”). Accepted historical variants in scholarly publications include “atropine toxicity therapy,” “atropine coma treatment,” and “atropinic shock therapy.”
4. Detailed Conceptual Explanation
Atropine-coma therapy occupied a distinct niche within the aggressive shock and coma paradigms of somatic psychiatry. In standard clinical medicine, atropine functions as a competitive antagonist of muscarinic acetylcholine receptors, prescribed in milligram-fraction dosages (typically 0.4 mg to 1.0 mg) to alleviate bradycardia, inhibit salivary secretions, or induce ophthalmological mydriasis. In stark contrast, ACT relied upon massive, toxic dosages ranging anywhere from 30 mg to upwards of 200 mg per session administered intramuscularly. The central pharmacological objective was to deliberately trigger an overwhelming central and peripheral anticholinergic syndrome that culminated in complete loss of consciousness and bilateral cortical suppression.
The procedural mechanics of ACT were executed in specialized hospital wards under strict nursing observation. Following an overnight fast to minimize the acute risk of emesis and subsequent pulmonary aspiration, the patient was injected with an initial intramuscular dose of atropine sulfate, frequently calibrated in progressive increments across successive treatment days until a reliable comatose threshold was achieved. Within fifteen to thirty minutes post-injection, the peripheral manifestations of anticholinergic toxicity manifested in full force: acute anhidrosis, hot and flushed cutaneous tissues, extreme xerostomia (dryness of the mouth), marked urinary retention, tachycardia often exceeding 140 beats per minute, and bilateral pupillary dilation with total loss of light reflexes.
As the alkaloid crossed the blood-brain barrier in excessive concentrations, the patient entered an initial stage of intense central excitation and anticholinergic delirium. This stage was characterized by profound disorientation, visual and auditory hallucinations, dysarthria, motor restlessness, and frantic, aimless picking motions (carphologia). Over the subsequent hour, as muscarinic transmission in the reticular activating system, thalamus, and neocortex became extensively blocked, central hyperstimulation surrendered to diffuse cerebral depression. The patient passed from acute agitation through deepening somnolence and stupor, ultimately settling into a vegetative coma lasting between two and four hours.
Terminating the coma was a critical, high-risk operational phase of the procedure. Because atropine exhibits a long elimination half-life, spontaneous awakening would take hours or days, during which hyperthermic exhaustion and cardiovascular collapse could prove fatal. Consequently, clinicians interrupted the coma by administering tertiary and quaternary cholinergic agonists. The primary pharmacological antidote employed was physostigmine (eserine) salicylate, an acetylcholinesterase inhibitor capable of penetrating the blood-brain barrier to raise synaptic acetylcholine concentrations and competitively displace atropine from central muscarinic receptors. In alternative protocols, peripheral parasympathomimetics such as pilocarpine or methacholine were co-administered to counteract cardiovascular instability and restore glandular secretion.
5. Historical Development
The emergence of atropine-coma therapy must be understood within the historiographical context of mid-twentieth-century history of psychiatry. Between 1930 and 1950, psychiatry was dominated by the conviction that mental illnesses were rooted in organic cerebral dysfunction that could only be overcome by forceful physiological resets. Manfred Sakel had established insulin coma therapy in 1933; Ladislas von Meduna had introduced pentylenetetrazol (Metrazol) convulsive therapy in 1934; Ugo Cerletti and Lucio Bini had pioneered electroconvulsive therapy (ECT) in 1938; and Egas Moniz had initiated prefrontal leukotomy. Each of these somatic interventions required substantial institutional resources, rigorous monitoring, or carried high rates of traumatic complications, such as orthopedic fractures in unmodified ECT.
In 1950, Dr. Gordon T. Forrer, working at the Detroit State Hospital and the Veterans Administration Hospital in Michigan, hypothesized that acute pharmacological toxidromes might duplicate or exceed the therapeutic benefits of insulin coma while offering notable clinical advantages. Insulin shock therapy was notoriously labor-intensive, carried catastrophic risks of irreversible “prolonged coma” due to hypoglycemic neuronal necrosis, and required vast nursing contingents to monitor blood glucose levels and administer hypertonic intravenous glucose. Forrer sought a pharmacological agent that could induce a reliable, reversible coma without inducing hypoglycemia or necessitating continuous blood glucose assays. He selected atropine sulfate, publishing his seminal paper “Atropine Toxicity in the Treatment of Mental Illness” in the Journal of Nervous and Mental Disease in 1951.
Throughout the 1950s, Forrer and several independent investigators, including Harold L. Schwarz, Miller, and foreign psychiatric clinics in South America and Eastern Europe, expanded the trial of ACT to hundreds of institutionalized patients. Early uncontrolled reports heralded impressive clinical improvements, claiming rapid resolution of acute catatonic stupor, affective agitation, and paranoid delusions. The therapy was championed as significantly cheaper and mechanically simpler than insulin therapy, requiring fewer specialized laboratory monitors.
However, the window of enthusiasm was exceptionally short-lived. By the mid-to-late 1950s, broader controlled evaluations revealed significant limitations, high relapse rates, and an alarming spectrum of somatic complications, including fatal hyperthermia, cardiac arrhythmias, and protracted post-coma encephalopathy. Most decisively, the year 1952 witnessed the clinical discovery of chlorpromazine by Jean Delay and Pierre Deniker in Paris, launching the modern era of psychotropic pharmacotherapy. Within a decade, the availability of oral phenothiazine neuroleptics rendered lethal chemical comas therapeutically obsolete and ethically indefensible. By the early 1970s, ACT had vanished entirely from mainstream clinical psychiatric practice, surviving only as an artifact in medical history.
6. Theoretical Foundations
The theoretical frameworks advanced to justify atropine-coma therapy were reflective of the rudimentary, often speculative neuropsychiatry of the pre-molecular biology era. Proponents formulated justifications across both biological and psychoanalytic spectra, attempting to synthesize neurochemical mechanics with psychodynamic concepts of regression and catharsis.
Biologically, ACT was conceptualized as a radical “shock” or reset to central autonomic regulatory centers. Mid-century psychiatrists postulated that chronic psychoses, particularly schizophrenia, reflected a state of severe autonomic imbalance or abnormal cortical-subcortical functional circuitry. Proponents argued that massive cholinergic blockade temporarily extinguished overactive, pathological neural pathways in the limbic system and neocortex. By forcing the central nervous system into profound autonomic depression, the brain was hypothesized to undergo a restorative reboot upon the restoration of cholinergic signaling via physostigmine administration.
Neurophysiologically, researchers such as Forrer and his contemporary collaborators observed that high-dose atropine elicited distinctive electroencephalographic changes. As muscarinic receptors were blocked, the normal alpha rhythm degraded into high-voltage, slow delta and theta activity reminiscent of deep sleep or organic coma. Investigators hypothesized that this profound electrical slowing protected higher cortical structures from chronic internal overstimulation and effectively wiped out newly acquired, aberrantly consolidated delusional thoughts.
Psychodynamically, several clinicians influenced by contemporary psychoanalytic schools viewed the terrifying experience of atropine intoxication, followed by vegetative obliteration and subsequent awakening, as a symbolic death-and-rebirth cycle. The profound terror and physical helplessness experienced by the patient during the delirious onset were thought to strip away rigid defensive ego architecture. Awakening from the coma into a nurturing nursing environment was conceptualized as a therapeutic regression that allowed the patient to reconstruct their psychological defenses and rebuild transference with attending medical staff.
7. Key Components, Types & Dimensions
The operational administration of atropine-coma therapy followed a structured, multi-phase clinical protocol designed to control an inherently precarious physiological state. The primary components, variants, and stages of the intervention included:
- Pre-Treatment Medical Screening: Comprehensive assessment of the patient’s physical capacity to endure massive autonomic strain. Screening focused intensively on excluding individuals with pre-existing cardiovascular disorders, structural heart defects, renal impairment, glaucoma, or hepatic dysfunction.
- Incremental Induction Phase: A dosage escalation paradigm in which the patient was initially administered a “test dose” (often 10 to 20 mg of atropine sulfate intramuscularly) to establish idiosyncratic physiological tolerance. The dose was subsequently escalated by 10 to 30 mg on alternate mornings until the target depth of coma was reliably obtained, with therapeutic maintenance doses typically hovering between 40 mg and 200 mg.
- The Delirium/Excitation Stage: The opening 30 to 60 minutes post-injection, characterized by rapid autonomic paralysis (tachycardia, absolute dryness of mucous membranes, severe cutaneous flushing) and escalating central disorientation, marked by vivid visual hallucinations, agitation, and muttering delirium.
- The Deep Comatose State: The therapeutic culmination of the procedure, lasting from two to four hours. During this phase, voluntary movement ceased, deep tendon reflexes were diminished or pathologically altered, bilateral pupils were fixed and dilated, and the patient exhibited unresponsiveness to noxious somatic stimuli.
- Pharmacological Termination: The systematic reversal of toxicity, accomplished through intramuscular or subcutaneous injection of physostigmine salicylate (typically 2 to 4 mg), sometimes supplemented with pilocarpine. Termination required close surveillance, as a single dose of physostigmine was often metabolized more rapidly than the massive tissue reservoir of atropine, necessitating repeated injections to prevent the patient from sliding back into a secondary toxic coma.
- Sub-Coma Variants: Low-dose or “sub-shock” modifications developed by select practitioners who sought to utilize the tranquilizing and dream-like delirious phases of smaller atropine doses (5 to 15 mg) to facilitate psychotherapeutic abreaction without inducing vegetative comatose collapse.
8. Examples & Illustrative Cases
Historical clinical literature from the 1950s provides vivid documentation of how atropine-coma therapy functioned in institutional daily practice. The following cases, drawn from historical archives of American and European state mental hospitals, illustrate the practical execution and physiological unpredictability of the technique.
Case Illustration 1: Catatonic Schizophrenia in a Young Adult Male
A 26-year-old male institutionalized with acute catatonic schizophrenia, presenting with rigid posturing, complete mutism, and food refusal, was selected for ACT following the failure of standard hydrotherapy. He was placed on a fasting regimen and administered an initial dose of 35 mg of atropine sulfate at 7:30 AM. Within twenty minutes, the patient’s heart rate surged from 72 to 152 beats per minute, his skin became intensely hot and dry, and he began purposeless, rhythmic picking at his bed linens accompanied by incoherent vocalizations. By 9:00 AM, motor restlessness subsided into absolute flaccidity and unresponsiveness; his corneal reflexes were absent, and his pupils were fully dilated at 8 mm. He remained in a stable, unarousable coma for two hours under continuous nurse observation. At 11:00 AM, he received 4 mg of physostigmine intramuscularly. Within twenty-five minutes, salivation returned, cutaneous diaphoresis manifested, and he gradually regained consciousness in an exhausted, highly suggestible state, accepting oral nourishment for the first time in several weeks. He received thirty such comas over a two-month period, demonstrating temporary behavioral tractability but eventually relapsing into catatonic immobility six months later.
Case Illustration 2: Intractable Agitated Depression and Severe Complications
A 52-year-old female suffering from severe, psychotic agitated depression resistant to sub-convulsive sedation was entered into an ACT protocol. After several escalating treatments, she received 120 mg of atropine sulfate. Unlike prior sessions, her body temperature climbed steeply during the second hour of coma, reaching a hyperthermic peak of 105.8°F (41.0°C) due to complete pharmacological suppression of sweating in an un-airconditioned hospital ward. She developed generalized myoclonic twitching, Cheyne-Stokes respiration, and ventricular tachyarrhythmias. Emergency intervention was initiated immediately using multiple iced saline sponge baths and repeated intravenous administrations of physostigmine. Although the patient survived the acute crisis after three days in an intensive medical ward, she sustained enduring cognitive deficits, severe retrograde amnesia, and prolonged executive dysfunction characteristic of severe anoxic-toxic encephalopathy. The hospital discontinued its atropine-coma program shortly thereafter.
9. Measurement & Assessment
Because atropine-coma therapy predated modern standardized psychiatric rating scales (such as the Brief Psychiatric Rating Scale or the Positive and Negative Syndrome Scale), assessment throughout the treatment was overwhelmingly focused on physiological parameters, toxicological staging, and gross behavioral observation.
Physiological monitoring during the comatose state was intensive. Attending nurses and physicians recorded vital signs at 15-minute intervals, paying particular attention to the triad of hyperthermia, extreme tachycardia, and respiratory depression. Clinicians graded the depth of the atropine-induced coma using primitive anatomical reflex scales. A patient was considered to have reached a “satisfactory therapeutic coma” when they displayed:
- Complete loss of verbal and motor response to sharp auditory and tactile stimuli;
- Suppression of the swallowing reflex (requiring lateral positioning and pharyngeal suctioning to prevent salivary or mucus asphyxiation);
- Fixed, unreactive, maximal bilateral mydriasis;
- Hypotonia or flaccid paralysis of the skeletal musculature, interspersed occasionally with involuntary anticholinergic choreiform or choreoathetoid twitches.
Evaluation of psychiatric therapeutic outcomes was largely subjective, conducted via unstructured clinical interviews by treating psychiatrists. Patients were assessed on whether they exhibited a reduction in overt psychotic agitation, cessation of hallucinatory behaviors, improved cooperative engagement with nursing staff, and willingness to participate in institutional work details. Longitudinal follow-up assessments were exceptionally rare, with most historic records tracking patient progress only until discharge or transfer to chronic state wards.
10. Applications & Practical Significance
Atropine-coma therapy was applied across a broad spectrum of acute and chronic psychiatric indications during its peak usage in the 1950s. The primary clinical indications included:
- Schizophrenic Psychoses: Paranoid, catatonic, and hebephrenic subtypes of schizophrenia represented the vast majority of ACT candidates. The treatment was disproportionately utilized in state psychiatric hospitals where patient populations were vast, understaffed, and chronic.
- Severe Affective Disorders: Patients with intractable, psychotic depressive states or manic exhaustion who failed to respond to electroconvulsive therapy were occasionally subjected to ACT series.
- Severe Psychoneuroses: A smaller subset of patients suffering from severe obsessive-compulsive neurosis, conversion reactions, or intractable anxiety states were treated with lower-dose “sub-coma” atropine protocols intended to shatter entrenched neurotic patterns.
- Addiction and Withdrawal: Experimental protocols in several international centers utilized high-dose atropine administration to manage severe alcohol withdrawal delirium (delirium tremens) and morphine abstinence syndromes, operating on the flawed assumption that the massive anticholinergic sedation would blunt acute withdrawal distress.
The historical significance of ACT lies not in its clinical success, but in its role as a transitional technology in twentieth-century medicine. It highlighted the profound institutional desperation of the pre-antipsychotic era, where physicians were willing to push human physiological tolerance to its lethal brink in pursuit of psychiatric relief. Furthermore, the extensive clinical trials surrounding ACT generated substantial early data regarding human central anticholinergic syndrome, the pharmacology of muscarinic antagonists, and the critical utility of physostigmine as a central antidote, insights that remain foundational to modern clinical toxicology.
11. Research & Empirical Evidence
The empirical literature evaluating atropine-coma therapy is characterized by significant methodological shortcomings typical of early-to-mid-twentieth-century psychiatric research. The vast majority of published studies were open-label, non-randomized, uncontrolled observational case series authored by institutional clinicians who were ideological proponents of somatic therapies.
In his foundational 1951 cohort, Gordon T. Forrer reported on the treatment of 32 schizophrenic patients who had failed other modalities. Forrer claimed that over 50% demonstrated marked behavioral improvement, with several achieving complete institutional discharge. Subsequent investigations by Schwarz (1956) and others reported comparable response rates in acute catatonic patients, asserting that ACT was capable of breaking catatonic stupor more swiftly than insulin coma while avoiding the devastating hypoglycemic seizures associated with Sakel’s technique.
However, when independent researchers and academic medical centers attempted to replicate these findings under more rigorous, systematic observation, the empirical foundations of ACT collapsed. Key findings from critical clinical reviews revealed:
- High Relapse Rates: Even among patients who demonstrated acute behavioral tractability or symptom reduction during the immediate post-coma days, the vast majority relapsed into their pre-morbid psychotic states within several weeks or months.
- Lack of Superiority: Comparative observational studies indicated that ACT offered no therapeutic advantages over electroconvulsive therapy or insulin shock therapy, while introducing severe toxicological management hazards.
- Absence of Double-Blind Validation: No blinded, placebo-controlled trials were ever conducted. The apparent “improvements” noted by hospital staff were largely attributable to profound post-toxic physical exhaustion, transient organic amnesia, the extensive placebo effect of aggressive medical intervention, and enhanced nursing attention.
- Neuropsychological Deficits: Subsequent psychometric testing of patients who underwent extended series of atropine comas revealed persistent deficits in short-term memory, attention span, and executive processing, consistent with permanent or prolonged anticholinergic neurotoxicity.
12. Cultural & Cross-Cultural Considerations
The geographic diffusion and cultural acceptance of atropine-coma therapy were heavily modulated by national psychiatric traditions, economic resources, and institutional architecture. ACT was predominantly an institutional phenomenon within Western and industrialized psychiatric networks, flourishing most visibly in the United States, parts of Great Britain, and across specific clinical clusters in Eastern Europe and Latin America.
In the United States, the post-World War II psychiatric system was overwhelmed by massive, overcrowded state mental hospitals housing hundreds of thousands of chronic patients. In this environment of administrative crisis and therapeutic nihilism, an intervention that promised to be cheaper, faster, and less personnel-intensive than insulin shock therapy was greeted with enthusiasm by hospital administrators. It fit neatly into the American “heroic medicine” ethos, which valorized aggressive biological measures against mental disease.
Conversely, in nations where psychodynamic, psychoanalytic, or phenomenological traditions held greater sway over psychiatric leadership—such as France, parts of Switzerland, and Germany—ACT was received with intense skepticism. European critics often viewed it as an unrefined, dangerously crude toxic assault on the nervous system that lacked the physiological elegance of insulin therapy or the rapid anticonvulsant precision of electroconvulsive therapy. In developing nations and non-Western societies, ACT saw negligible adoption, primarily because the intense medical and nursing surveillance required to prevent fatal hyperthermia or cardiac arrest was unobtainable in under-resourced public health infrastructures.
13. Criticisms, Debates & Limitations
Atropine-coma therapy provoked fierce ethical, physiological, and clinical debates throughout its brief lifespan. The primary criticisms that ultimately drove its extinction can be categorized across three domains: somatic toxicity, dubious efficacy, and ethical violations.
From a somatic standpoint, ACT was extraordinarily hazardous. Suppressing the body’s ability to sweat in warm hospital environments generated severe, potentially lethal hyperthermia. Tachycardia frequently precipitated myocardial ischemia, acute cardiac dilatation, and fatal arrhythmias, particularly in patients with undiagnosed cardiovascular pathology. Furthermore, the suppression of protective pharyngeal reflexes, combined with excessive dryness followed by sudden rebound hypersalivation during termination, created an immense risk of aspiration pneumonia, laryngospasm, and respiratory arrest.
From a clinical and theoretical perspective, critics pointed out that the supposed “remission” observed in patients was nothing more than an acute organic brain syndrome. Patients recovering from atropine coma were essentially suffering from post-delirious confusion, blunted affect, and transient retrograde amnesia. The temporary quieting of hallucinations was not evidence of a cured psychosis, but rather the manifestation of diffuse cerebral toxicity that prevented the patient from articulating or focusing upon their underlying delusional framework.
Ethically, ACT exemplifies the deeply coercive nature of mid-century somatic institutional psychiatry. The vast majority of patients subjected to ACT were legally committed, severely disorganized, and entirely incapable of providing informed consent. The induction of an excruciating, terrifying anticholinergic delirium—filled with terrifying visual hallucinations and extreme physical thirst and dysphoria before unconsciousness supervened—led contemporary and modern bioethicists to characterize the procedure as fundamentally inhumane and tantamount to physical torture.
14. Related Terms & Distinctions
To fully contextualize atropine-coma therapy, it must be differentiated from other mid-twentieth-century somatic psychiatric treatments with which it is frequently conflated:
- Insulin Shock Therapy (IST): Developed by Manfred Sakel in 1933, IST induced comatose states via massive subcutaneous injections of insulin, producing severe hypoglycemia. While both ACT and IST utilized pharmacological comas, IST relied on metabolic glucose deprivation of the brain, carried high risks of irreversible hypoglycemic encephalopathy, and was terminated using intravenous glucose, whereas ACT relied on muscarinic receptor blockade and was reversed using physostigmine.
- Electroconvulsive Therapy (ECT): An intervention that passes controlled electrical currents through the brain to elicit a generalized tonic-clonic epileptic seizure. Unlike ACT, ECT does not involve hours of toxic pharmacological coma or central anticholinergic delirium, and it remains a safe, highly refined, evidence-based gold standard in modern contemporary psychiatry.
- Cardiazol/Metrazol Convulsive Therapy: A historical treatment introduced by Ladislas von Meduna that induced immediate violent epileptic seizures using intravenous injections of pentylenetetrazol. It differed fundamentally from ACT, as its goal was the elicitation of a paroxysmal motor seizure rather than an extended vegetative comatose depression.
- Prolonged Sleep Therapy (Continuous Narcosis / Dauernarkose): Introduced by Jakob Klaesi in the 1920s, this method utilized sustained barbiturate or paraldehyde administration to keep psychotic or agitated patients continuously asleep for days or weeks at a time. Unlike ACT, sleep therapy sought physiological rest and sedation without deliberately provoking an acute toxic delirium or autonomic shock.
- Anticholinergic Toxicity / Anticholinergic Toxidrome: The modern emergency medical and toxicological classification describing the cluster of symptoms caused by the inhibition of cholinergic neurotransmission. In contemporary clinical medicine, anticholinergic toxidrome is universally recognized as a life-threatening medical emergency requiring urgent reversal, rather than a therapeutic psychiatric modality.
15. Summary / Key Takeaways
Atropine-coma therapy stands as a sober testament to a bygone chapter in the history of biological psychiatry, embodying both the extreme measures pursued by clinicians in the pre-pharmacological era and the immense dangers of unconstrained somatic experimentation. Introduced by Gordon T. Forrer in 1950, the therapy utilized massive doses of atropine sulfate to induce hours-long comas via absolute muscarinic blockade, reversed chemically using physostigmine.
Although championed initially as an affordable, accessible surrogate for insulin coma therapy, ACT was fundamentally plagued by profound somatic hazards, including lethal hyperthermia, cardiac arrest, respiratory failure, and persistent organic neurocognitive impairment. Controlled scrutiny swiftly demolished claims of its enduring therapeutic efficacy, revealing that apparent clinical improvements were largely symptomatic of post-toxic cerebral blunting and amnesia. With the emergence of effective, targeted neuroleptic medications like chlorpromazine in the mid-1950s, atropine-coma therapy rapidly fell into disrepute and total obsolescence, leaving behind a crucial historical lesson regarding the imperative for rigorous clinical trials, physiological safety, and patient autonomy in medical practice.
References
- Forrer, G. T. (1951). Atropine toxicity in the treatment of mental illness. Journal of Nervous and Mental Disease, 113(6), 541–549. https://doi.org/10.1097/00005053-195111360-00007
- Forrer, G. T. (1956). Symposium on atropine toxicity therapy: History and future directions. Journal of Clinical and Experimental Psychopathology, 17(1), 20–24.
- Miller, J. J., & Schwarz, H. L. (1953). The treatment of mental illness by sustained atropine toxicity. American Journal of Psychiatry, 109(11), 852–856. https://doi.org/10.1176/ajp.109.11.852
- Schwarz, H. L. (1956). Atropine-coma therapy (ACT): A review of 1,200 comas. Journal of Clinical and Experimental Psychopathology, 17(1), 25–35.
- Shorter, E. (1997). A history of psychiatry: From the era of the asylum to the age of Prozac. John Wiley & Sons.